The group now plans to run the 32-gene panel in clinical trials to demonstrate its utility and make the case for offering it within Canada's healthcare system.
The two companies are entering a partnership to introduce diagnostic tests using NanoString's nCounter technology in Japan, beginning with a lymphoma assay.
Having demonstrated their ATR-FTIR technique in mice, the researchers are moving to human samples and they plan to be in clinical trials in around two years.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
The firm said that entry into the market is a logical progression based on its existing position and strength in hematology, an adjacent segment.
The firm recently announced that it is developing a new range of clinical flow systems that it expects to launch over the next five years.
The test, the agency said, is the first authorized by it for use with flow cytometry to detect leukemias and lymphomas.
The firm's first assay will be for Hodgkin lymphoma, but a liquid biopsy test for prostate cancer has also shown strong predictive power in initial validation data.
The companies will initially focus on developing a companion diagnostic for Merck's investigational B cell lymphoma drug M7583.
The company said its HTG EdgeSeq system and EdgeSeq Diffuse Large B-Cell Lymphoma Cell of Origin Assay may now be distributed in the EU.